Jingang Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jingang Xiao has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
Pengcheng Rao
Luzhou Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, the Affiliated Stomatological Hospital Southwest Medical University Luzhou China
10 shared publicationsShuanglin Peng
Department of Oral Implantology, The Affiliated Stomatological Hospital, Southwest Medical University, Luzhou, 646000, China
10 shared publicationsFangzhi Lou
Luzhou Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, The Affiliated Stomatological Hospital, Southwest Medical University, Luzhou, China
9 shared publicationsKui Huang
9 shared publicationsXiaorong Lan
Luzhou Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration Luzhou China
9 shared publicationsMaorui Zhang
Luzhou Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, The Affiliated Stomatological Hospital, Southwest Medical University, Luzhou, 646000, China.
7 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Springer Nature in International Journal of Oral Science
- Vol. 18 (1) , 72
Author Correction: The YTHDC1-m6A-GADD45B axis promotes chondrogenesis of hPDLSCs via suppressing senescence through p53/p21 signalling pathway
- 31 October 2026
- Published by Springer Nature in International Journal of Oral Science
- Vol. 18 (1) , 72
Open AccessAuthor Correction: The YTHDC1-m6A-GADD45B axis promotes chondrogenesis of hPDLSCs via suppressing senescence through p53/p21 signalling pathway
- Open Access
- 8 September 2026
- Published by Tsinghua University Press in Oral Science and Homeostatic Medicine
- Vol. 2 (3)
The oral–gut microbiome axis in systemic bone-related diseases
The oral microbiome is increasingly recognized as an upstream ecological interface with systemic relevance beyond oral disease. Emerging evidence links oral dysbiosis to skeletal pathology through an oral–gut axis involving salivary microbial transfer, gut remodeling, barrier dysfunction, and microbiota-derived metabolites. In this review, we summarize current evidence supporting the oral–gut–bone axis in systemic bone-related diseases and propose an integrated framework in which oral ecological disturbance may contribute to skeletal vulnerability through gut-dependent metabolic and inflammatory relay mechanisms. We highlight three major mechanistic architectures: metabolite-centered osteoimmune regulation, barrier dysfunction with inflammatory amplification, and oral-derived microbial signaling. Across rheumatoid arthritis, osteoarthritis, and osteoporosis, these pathways are associated with distinct downstream phenotypes, including inflammatory bone erosion, degenerative joint remodeling, and systemic bone loss. Short-chain fatty acids, valeric acid, bile acid derivatives, and tryptophan-derived indoles emerge as key intermediates linking microbial ecology to osteoclastogenesis, osteoblast activity, immune polarization, and joint homeostasis. We also discuss translational opportunities involving metabolite restoration, microbiota-targeted intervention, host-pathway modulation, and mechanism-guided biomarker development. Despite recent progress, most current evidence remains associative, and major gaps persist in causal inference and functional validation.
- 8 September 2026
- Published by Tsinghua University Press in Oral Science and Homeostatic Medicine
- Vol. 2 (3)
Open AccessThe oral–gut microbiome axis in systemic bone-related diseases
The oral microbiome is increasingly recognized as an upstream ecological interface with systemic relevance beyond oral disease. Emerging evidence links oral dysbiosis to skeletal pathology through an oral–gut axis involving salivary microbial transfer, gut remodeling, barrier dysfunction, and microbiota-derived metabolites. In this review, we summarize current evidence supporting the oral–gut–bone axis in systemic bone-related diseases and propose an integrated framework in which oral ecological disturbance may contribute to skeletal vulnerability through gut-dependent metabolic and inflammatory relay mechanisms. We highlight three major mechanistic architectures: metabolite-centered osteoimmune regulation, barrier dysfunction with inflammatory amplification, and oral-derived microbial signaling. Across rheumatoid arthritis, osteoarthritis, and osteoporosis, these pathways are associated with distinct downstream phenotypes, including inflammatory bone erosion, degenerative joint remodeling, and systemic bone loss. Short-chain fatty acids, valeric acid, bile acid derivatives, and tryptophan-derived indoles emerge as key intermediates linking microbial ecology to osteoclastogenesis, osteoblast activity, immune polarization, and joint homeostasis. We also discuss translational opportunities involving metabolite restoration, microbiota-targeted intervention, host-pathway modulation, and mechanism-guided biomarker development. Despite recent progress, most current evidence remains associative, and major gaps persist in causal inference and functional validation.
- Open Access
- 2 September 2026
- Published by Springer Nature in BMC Oral Health
The CCL3-CCR1 axis promotes corticotomy-accelerated orthodontic tooth movement by regulating M1 macrophage polarization
Background: Corticotomy promotes bone remodeling through the regional acceleratory phenomenon (RAP) and is a commonly used surgical procedure to accelerate orthodontic tooth movement (OTM). However, the molecular mechanisms underlying RAP remain incompletely understood, which limits the development of non‑invasive strategies to accelerate tooth movement based on this phenomenon. Accumulating evidence supports that M1 macrophages serve as key effector cells in RAP. C‑C motif chemokine ligand 3 (CCL3) and its receptors are important regulators of macrophage polarization, but their specific role in corticotomy‑induced RAP has not yet been elucidated. Methods: After establishing a rat model of orthodontic tooth movement combined with corticotomy (OTM + CO) in male rats, changes in the CCL3‑CCR1 axis and in macrophages during corticotomy‑accelerated osteoclast differentiation were examined by reverse transcription‑polymerase chain reaction (RT‑qPCR), Western blotting, and immunofluorescence staining. Subsequently, RAW264.7 cells were treated with recombinant CCL3 (rCCL3) or transfected with lentivirus to modulate the CCL3‑CCR1 axis, and the effect of this axis on macrophage polarization was assessed using flow cytometry, among other methods. Finally, following local periodontal injection of the CCR1 antagonist BX471 into the OTM + CO model, micro‑computed tomography (micro‑CT), hematoxylin and eosin (H&E) staining, and tartrate‑resistant acid phosphatase (TRAP) staining were employed to determine whether CCR1 inhibition in macrophages attenuates the corticotomy‑induced effects on tooth movement distance, bone resorption, and macrophage polarization status. Results: Corticotomy specifically activated the CCL3-CCR1 signaling axis in mechanically stimulated alveolar bone and significantly upregulated the expression of M1 macrophage markers. Recombinant CCL3 enhanced macrophage polarization toward the M1 phenotype through CCR1 binding. This polarization effect was significantly reversed when CCR1 expression was knocked down in macrophages, as determined by lentiviral transduction. Animal experiments further demonstrated that CCR1 inhibition effectively blocked corticotomy-induced macrophage polarization toward the M1 phenotype and suppressed bone remodeling acceleration. Conclusions: The CCL3-CCR1 axis plays an important role in corticotomy-induced RAP through driving M1 macrophage polarization, thereby promoting alveolar bone remodeling and accelerating OTM. These findings revealed a novel mechanism underlying corticotomy-promoted tooth movement and offered important theoretical support for the development of non-surgical strategies to increase the efficiency of orthodontic treatment.
- 2 September 2026
- Published by Springer Nature in BMC Oral Health
Open AccessThe CCL3-CCR1 axis promotes corticotomy-accelerated orthodontic tooth movement by regulating M1 macrophage polarization
Background: Corticotomy promotes bone remodeling through the regional acceleratory phenomenon (RAP) and is a commonly used surgical procedure to accelerate orthodontic tooth movement (OTM). However, the molecular mechanisms underlying RAP remain incompletely understood, which limits the development of non‑invasive strategies to accelerate tooth movement based on this phenomenon. Accumulating evidence supports that M1 macrophages serve as key effector cells in RAP. C‑C motif chemokine ligand 3 (CCL3) and its receptors are important regulators of macrophage polarization, but their specific role in corticotomy‑induced RAP has not yet been elucidated. Methods: After establishing a rat model of orthodontic tooth movement combined with corticotomy (OTM + CO) in male rats, changes in the CCL3‑CCR1 axis and in macrophages during corticotomy‑accelerated osteoclast differentiation were examined by reverse transcription‑polymerase chain reaction (RT‑qPCR), Western blotting, and immunofluorescence staining. Subsequently, RAW264.7 cells were treated with recombinant CCL3 (rCCL3) or transfected with lentivirus to modulate the CCL3‑CCR1 axis, and the effect of this axis on macrophage polarization was assessed using flow cytometry, among other methods. Finally, following local periodontal injection of the CCR1 antagonist BX471 into the OTM + CO model, micro‑computed tomography (micro‑CT), hematoxylin and eosin (H&E) staining, and tartrate‑resistant acid phosphatase (TRAP) staining were employed to determine whether CCR1 inhibition in macrophages attenuates the corticotomy‑induced effects on tooth movement distance, bone resorption, and macrophage polarization status. Results: Corticotomy specifically activated the CCL3-CCR1 signaling axis in mechanically stimulated alveolar bone and significantly upregulated the expression of M1 macrophage markers. Recombinant CCL3 enhanced macrophage polarization toward the M1 phenotype through CCR1 binding. This polarization effect was significantly reversed when CCR1 expression was knocked down in macrophages, as determined by lentiviral transduction. Animal experiments further demonstrated that CCR1 inhibition effectively blocked corticotomy-induced macrophage polarization toward the M1 phenotype and suppressed bone remodeling acceleration. Conclusions: The CCL3-CCR1 axis plays an important role in corticotomy-induced RAP through driving M1 macrophage polarization, thereby promoting alveolar bone remodeling and accelerating OTM. These findings revealed a novel mechanism underlying corticotomy-promoted tooth movement and offered important theoretical support for the development of non-surgical strategies to increase the efficiency of orthodontic treatment.
- Open Access
- 29 June 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Aptamer-functionalized tetrahedral framework nucleic acid delivery of siBhlhe22 for repairing osteoporotic bone defects via dual modulation of PI3K-Akt signaling and purine metabolism
Osteoporosis is characterized by an imbalance between bone formation and resorption, and the dysregulated differentiation of bone marrow mesenchymal stem cells (BMSCs) plays a central role. Our previous study identified Bhlhe22 as a key negative regulator of osteogenic differentiation; here, we further validate its role in osteoporotic BMSCs (OP-BMSCs) and investigate its therapeutic potential. Knocking down Bhlhe22 enhanced osteogenesis by upregulating key osteogenic markers (RUNX2, ALP, OPN) and suppressing the PI3K-Akt signaling pathway. To enable targeted delivery of siBhlhe22, we designed an aptamer-functionalized tetrahedral framework nucleic acid-based nanocarrier (Apt19S-tFNA-siBhlhe22, ATS). The ATS system exhibited well-defined nanostructure, excellent biocompatibility, and high cellular uptake efficiency in OP-BMSCs. In vitro, ATS-mediated Bhlhe22 knockdown significantly promoted osteogenic differentiation and matrix mineralization. This effect depended on the inhibition of PI3K-Akt signaling, as demonstrated by rescue experiments using the agonist Recilisib. Non-targeted metabolomics revealed that osteoporosis was associated with disruption of nucleotide and purine metabolism, which was effectively reversed by ATS treatment. Functional studies confirmed that intact purine metabolism, which was essential for ATP production and redox balance, was required for the pro-osteogenic effect of ATS. In an osteoporotic rat bone defect model, ATS delivered via GelMA hydrogel promoted bone regeneration. This was accompanied by in vivo suppression of PI3K-Akt signaling and upregulation of OCN and OPN. Our findings establish a novel gene therapy strategy that targets Bhlhe22 to simultaneously modulate pro-osteogenic signaling and metabolic reprogramming, offering a promising anabolic approach for osteoporosis treatment.
- 29 June 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessAptamer-functionalized tetrahedral framework nucleic acid delivery of siBhlhe22 for repairing osteoporotic bone defects via dual modulation of PI3K-Akt signaling and purine metabolism
Osteoporosis is characterized by an imbalance between bone formation and resorption, and the dysregulated differentiation of bone marrow mesenchymal stem cells (BMSCs) plays a central role. Our previous study identified Bhlhe22 as a key negative regulator of osteogenic differentiation; here, we further validate its role in osteoporotic BMSCs (OP-BMSCs) and investigate its therapeutic potential. Knocking down Bhlhe22 enhanced osteogenesis by upregulating key osteogenic markers (RUNX2, ALP, OPN) and suppressing the PI3K-Akt signaling pathway. To enable targeted delivery of siBhlhe22, we designed an aptamer-functionalized tetrahedral framework nucleic acid-based nanocarrier (Apt19S-tFNA-siBhlhe22, ATS). The ATS system exhibited well-defined nanostructure, excellent biocompatibility, and high cellular uptake efficiency in OP-BMSCs. In vitro, ATS-mediated Bhlhe22 knockdown significantly promoted osteogenic differentiation and matrix mineralization. This effect depended on the inhibition of PI3K-Akt signaling, as demonstrated by rescue experiments using the agonist Recilisib. Non-targeted metabolomics revealed that osteoporosis was associated with disruption of nucleotide and purine metabolism, which was effectively reversed by ATS treatment. Functional studies confirmed that intact purine metabolism, which was essential for ATP production and redox balance, was required for the pro-osteogenic effect of ATS. In an osteoporotic rat bone defect model, ATS delivered via GelMA hydrogel promoted bone regeneration. This was accompanied by in vivo suppression of PI3K-Akt signaling and upregulation of OCN and OPN. Our findings establish a novel gene therapy strategy that targets Bhlhe22 to simultaneously modulate pro-osteogenic signaling and metabolic reprogramming, offering a promising anabolic approach for osteoporosis treatment.
- Open Access
- 15 June 2026
- Published by Springer Nature in International Journal of Oral Science
- Vol. 18 (1) , 46
The YTHDC1-m6A-GADD45B axis promotes chondrogenesis of hPDLSCs via suppressing senescence through p53/p21 signalling pathway
Temporomandibular joint osteoarthritis (TMJOA) is a degenerative disease with limited therapeutic options. Stem cell-based tissue engineering, particularly utilizing human periodontal ligament stem cells (hPDLSCs), represents a promising approach for cartilage regeneration. However, we have previously demonstrated that chronic inflammation and hypoxic stress in the TMJOA microenvironment markedly accelerate cellular senescence in hPDLSCs, severely impairing their regenerative potential. Here, we identify the YTHDC1–m⁶A–GADD45B axis as a critical regulator of senescence and chondrogenic differentiation in hPDLSCs. We show that YTHDC1, an m⁶A reader protein, is downregulated under inflammatory and senescent conditions. Functional studies reveal that YTHDC1 overexpression attenuates senescence and enhances chondrogenesis, whereas its knockdown exacerbates senescence and suppresses differentiation. Mechanistically, YTHDC1 recognizes m⁶A modifications on GADD45B mRNA and promotes its decay, leading to inhibition of the p53/p21 signaling pathway. Mutation of the m⁶A site in GADD45B abolishes the regulatory effects of YTHDC1. In rats with TMJOA, transplantation of YTHDC1–overexpressing hPDLSCs ameliorated disease phenotypes, an effect reversed by co-expression of wild-type GADD45B. Our findings reveal a novel epitranscriptomic mechanism that regulates hPDLSCs senescence and subsequently affects chondrogenic differentiation, and highlight the therapeutic potential of targeting the YTHDC1-GADD45B-p53/p21 axis.
- 15 June 2026
- Published by Springer Nature in International Journal of Oral Science
- Vol. 18 (1) , 46
Open AccessThe YTHDC1-m6A-GADD45B axis promotes chondrogenesis of hPDLSCs via suppressing senescence through p53/p21 signalling pathway
Temporomandibular joint osteoarthritis (TMJOA) is a degenerative disease with limited therapeutic options. Stem cell-based tissue engineering, particularly utilizing human periodontal ligament stem cells (hPDLSCs), represents a promising approach for cartilage regeneration. However, we have previously demonstrated that chronic inflammation and hypoxic stress in the TMJOA microenvironment markedly accelerate cellular senescence in hPDLSCs, severely impairing their regenerative potential. Here, we identify the YTHDC1–m⁶A–GADD45B axis as a critical regulator of senescence and chondrogenic differentiation in hPDLSCs. We show that YTHDC1, an m⁶A reader protein, is downregulated under inflammatory and senescent conditions. Functional studies reveal that YTHDC1 overexpression attenuates senescence and enhances chondrogenesis, whereas its knockdown exacerbates senescence and suppresses differentiation. Mechanistically, YTHDC1 recognizes m⁶A modifications on GADD45B mRNA and promotes its decay, leading to inhibition of the p53/p21 signaling pathway. Mutation of the m⁶A site in GADD45B abolishes the regulatory effects of YTHDC1. In rats with TMJOA, transplantation of YTHDC1–overexpressing hPDLSCs ameliorated disease phenotypes, an effect reversed by co-expression of wild-type GADD45B. Our findings reveal a novel epitranscriptomic mechanism that regulates hPDLSCs senescence and subsequently affects chondrogenic differentiation, and highlight the therapeutic potential of targeting the YTHDC1-GADD45B-p53/p21 axis.
- Open Access
- 3 June 2026
- Published by Wiley in Cell Proliferation
- Vol. 59 (11) , e70240
YTHDF3 Enhances Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells in Osteoporosis by Promoting TBX19 Expression
N 6 ‐methyladenosine (m 6 A) modification is critically involved in regulating the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), yet the functional contributions of m 6 A reader proteins in osteoporosis remain poorly defined. In this study, we found that osteoporosis in rats correlates with severe bone loss and diminished osteogenic potential of BMSCs, accompanied by down‐regulation of the m 6 A reader YTHDF3. Functional assays showed that YTHDF3 promotes osteogenic differentiation of BMSCs. RNA‐sequencing analysis identified the transcription factor TBX19 as a key downstream mediator of YTHDF3. Subsequent investigations confirmed that Tbx19 knockdown not only attenuated the osteogenic capacity of BMSCs but also abrogated the pro‐osteogenic effect of Ythdf3 overexpression. Moreover, in vivo experiments demonstrated that Ythdf3 overexpression enhances the bone‐forming ability of osteoporotic BMSCs. Collectively, our results reveal that YTHDF3 acts as a positive regulator of BMSC osteogenesis, largely through regulating TBX19, and that its down‐regulation contributes to osteoporotic pathogenesis. These findings propose YTHDF3 as a novel potential therapeutic target for the treatment of osteoporosis.
- 3 June 2026
- Published by Wiley in Cell Proliferation
- Vol. 59 (11) , e70240
Open AccessYTHDF3 Enhances Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells in Osteoporosis by Promoting TBX19 Expression
N 6 ‐methyladenosine (m 6 A) modification is critically involved in regulating the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), yet the functional contributions of m 6 A reader proteins in osteoporosis remain poorly defined. In this study, we found that osteoporosis in rats correlates with severe bone loss and diminished osteogenic potential of BMSCs, accompanied by down‐regulation of the m 6 A reader YTHDF3. Functional assays showed that YTHDF3 promotes osteogenic differentiation of BMSCs. RNA‐sequencing analysis identified the transcription factor TBX19 as a key downstream mediator of YTHDF3. Subsequent investigations confirmed that Tbx19 knockdown not only attenuated the osteogenic capacity of BMSCs but also abrogated the pro‐osteogenic effect of Ythdf3 overexpression. Moreover, in vivo experiments demonstrated that Ythdf3 overexpression enhances the bone‐forming ability of osteoporotic BMSCs. Collectively, our results reveal that YTHDF3 acts as a positive regulator of BMSC osteogenesis, largely through regulating TBX19, and that its down‐regulation contributes to osteoporotic pathogenesis. These findings propose YTHDF3 as a novel potential therapeutic target for the treatment of osteoporosis.
- Open Access
- 2 June 2026
- Published by Elsevier in SSRN Electronic Journal
A Bone-Homing DNA Tetrahedral Framework Nucleic Acids Nanodevice Orchestrates Osteogenic Regeneration to Rescue Postmenopausal Osteoporosis
Postmenopausal osteoporosis (PMOP) represents a pervasive metabolic crisis driven by a dysregulated bone microenvironment, where the chronic inflammation leads to rapid deterioration of bone microstructure. However, the clinical management of PMOP remains fundamentally limited by a “delivery dilemma”: conventional osteogenic agents suffer from abysmal bioavailability, rapid systemic clearance, and indiscriminate biodistribution, often necessitating high doses that induce severe extraskeletal toxicity. To overcome these physiological barriers, a programmable, bone-homing nanotherapeutic strategy needs to be engineered. First, tFNA is conjugated with the osteogenic targeting peptide (SDSSD) to confer bone-homing capability. Genistein (Gen) is then encapsulated within the rigid DNA nanocage of tFNA-SDSSD, forming a multifunctional nanodevice (tFNA-SDSSD/Gen) with high cellular uptake efficiency and efficient bone-homing. Mechanistic studies reveal that tFNA-SDSSD/Gen acts as a "molecular switch" to reverse inflammation-induced osteogenic arrest of osteoblasts within the PMOP microenvironment by synergistically activating the PI3K/AKT and MAPK signaling cascades. Systemic administration in ovariectomized mice significantly mitigates trabecular bone loss and restores bone microarchitecture quality with negligible off-target toxicity. These findings demonstrate the great potential of tFNA-SDSSD/Gen in the treatment of osteoporosis, thus providing a robust strategy for targeted therapy of metabolic bone diseases.
- 2 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Bone-Homing DNA Tetrahedral Framework Nucleic Acids Nanodevice Orchestrates Osteogenic Regeneration to Rescue Postmenopausal Osteoporosis
Postmenopausal osteoporosis (PMOP) represents a pervasive metabolic crisis driven by a dysregulated bone microenvironment, where the chronic inflammation leads to rapid deterioration of bone microstructure. However, the clinical management of PMOP remains fundamentally limited by a “delivery dilemma”: conventional osteogenic agents suffer from abysmal bioavailability, rapid systemic clearance, and indiscriminate biodistribution, often necessitating high doses that induce severe extraskeletal toxicity. To overcome these physiological barriers, a programmable, bone-homing nanotherapeutic strategy needs to be engineered. First, tFNA is conjugated with the osteogenic targeting peptide (SDSSD) to confer bone-homing capability. Genistein (Gen) is then encapsulated within the rigid DNA nanocage of tFNA-SDSSD, forming a multifunctional nanodevice (tFNA-SDSSD/Gen) with high cellular uptake efficiency and efficient bone-homing. Mechanistic studies reveal that tFNA-SDSSD/Gen acts as a "molecular switch" to reverse inflammation-induced osteogenic arrest of osteoblasts within the PMOP microenvironment by synergistically activating the PI3K/AKT and MAPK signaling cascades. Systemic administration in ovariectomized mice significantly mitigates trabecular bone loss and restores bone microarchitecture quality with negligible off-target toxicity. These findings demonstrate the great potential of tFNA-SDSSD/Gen in the treatment of osteoporosis, thus providing a robust strategy for targeted therapy of metabolic bone diseases.
- Open Access
- 20 April 2026
- Published by The Korean Society of Food Science and Nutrition in Preventive Nutrition and Food Science
- Vol. 31 (2)
Flavonoids of Cuscuta chinensis Enhance Osteogenic Differentiation in Dental Pulp Stem Cells via the Regulation of Wnt/β-Catenin Signaling
Osteoporosis renders postmenopausal women susceptible to alveolar bone loss and complicates dental care, highlighting the urgent need for devising safe and effective nutritional strategies that support bone health. Cuscuta chinensis, a traditional medicinal plant, contains flavonoids with reported bioactivity on bone metabolism. This study aimed to evaluate the osteogenic potential of the total flavonoids of C. chinensis (TFCC) using human dental pulp stem cells (HDPSCs) and establish their preventive relevance for osteoporosis management. HDPSCs were treated with TFCC, and osteogenic differentiation was assessed employing alkaline phosphatase activity, Alizarin red S staining, wound-healing assay, RNA sequencing, and Western blotting of Wnt/β-catenin pathway proteins. TFCC at low concentrations enhanced HDPSC proliferation and markedly promoted osteogenic differentiation, as evidenced by elevated mineralized nodule formation and accelerated wound closure. Transcriptomic and protein analyses confirmed the activation of the Wnt/β-catenin signaling pathway, including an upregulation of runt-related transcription factor 2, osteopontin, β-catenin, and lymphoid enhancer-binding factor 1, with a concomitant phosphorylation of glycogen synthase kinase-3 β. Additionally, TFCC also mitigated the inhibitory effects of the Wnt inhibitor XAV-939. These findings indicate enhanced osteogenic differentiation in response to TFCC treatment, a process that may involve Wnt/β-catenin pathway modulation. Our results suggest that TFCC may serve as a diet component for maintaining bone health in menopausal women, offering new translational potential for osteoporosis-related dental care.
- 20 April 2026
- Published by The Korean Society of Food Science and Nutrition in Preventive Nutrition and Food Science
- Vol. 31 (2)
Open AccessFlavonoids of Cuscuta chinensis Enhance Osteogenic Differentiation in Dental Pulp Stem Cells via the Regulation of Wnt/β-Catenin Signaling
Osteoporosis renders postmenopausal women susceptible to alveolar bone loss and complicates dental care, highlighting the urgent need for devising safe and effective nutritional strategies that support bone health. Cuscuta chinensis, a traditional medicinal plant, contains flavonoids with reported bioactivity on bone metabolism. This study aimed to evaluate the osteogenic potential of the total flavonoids of C. chinensis (TFCC) using human dental pulp stem cells (HDPSCs) and establish their preventive relevance for osteoporosis management. HDPSCs were treated with TFCC, and osteogenic differentiation was assessed employing alkaline phosphatase activity, Alizarin red S staining, wound-healing assay, RNA sequencing, and Western blotting of Wnt/β-catenin pathway proteins. TFCC at low concentrations enhanced HDPSC proliferation and markedly promoted osteogenic differentiation, as evidenced by elevated mineralized nodule formation and accelerated wound closure. Transcriptomic and protein analyses confirmed the activation of the Wnt/β-catenin signaling pathway, including an upregulation of runt-related transcription factor 2, osteopontin, β-catenin, and lymphoid enhancer-binding factor 1, with a concomitant phosphorylation of glycogen synthase kinase-3 β. Additionally, TFCC also mitigated the inhibitory effects of the Wnt inhibitor XAV-939. These findings indicate enhanced osteogenic differentiation in response to TFCC treatment, a process that may involve Wnt/β-catenin pathway modulation. Our results suggest that TFCC may serve as a diet component for maintaining bone health in menopausal women, offering new translational potential for osteoporosis-related dental care.
- Open Access
- 23 February 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
m6A-mediated stabilization of Bhlhe22 suppresses osteogenesis in osteoporosis by activating the PI3K-AKT-GSK3β signaling axis
Impaired osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) contributes to osteoporosis (OP) pathogenesis. While RNA modifications su
- 23 February 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open Accessm6A-mediated stabilization of Bhlhe22 suppresses osteogenesis in osteoporosis by activating the PI3K-AKT-GSK3β signaling axis
Impaired osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) contributes to osteoporosis (OP) pathogenesis. While RNA modifications su